Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | SULT1E1 | P49888 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11447483 | 0.77 | EP300 (0.48) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14881442 | 0.77 | EP300 (0.48) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL16010773 | 0.77 | EP300 (0.48) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14880057 | 0.73 | EP300 (0.45) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14881395 | 0.73 | EP300 (0.45) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL16010952 | 0.73 | EP300 (0.54) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL14882079 | 0.73 | EP300 (0.54) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL16010777 | 0.73 | EP300 (0.45) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL16010788 | 0.73 | EP300 (0.45) | EP300USP2ALDH1A1CYP3A4MAPT | |
| SCHEMBL16010743 | 0.70 | EP300 (0.42) | EP300USP2ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | claimed |
| US-9499464-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | claimed |
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9499464-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | EP300 4044/4885USP2 4166/4885ALDH1A1 2166/4885 |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, PDE6C, CRYAA | EP300 4137/4885USP2 4138/4885ALDH1A1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.